Citius Oncology 2025年第一季度GAAP每股收益$(1.30) 低于$(0.06)预估

财报速递
15 Feb
Citius Oncology (NASDAQ:CTOR)报告季度每股亏损$(1.30),比分析师预期的$(0.06)低了2066.67%。

以上内容来自Benzinga Earnings专栏,原文如下:

Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(0.06) by 2066.67 percent.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10